American Academy of Pediatrics and other medical experts exclusively recommend to breastfeed the baby for first 6 months. Once you introduce baby to other foods it is recommended to breastfeed for at least first year of babys life. Taking medication while breastfeeding could be tricky as most drugs pass in breast milk. In this article we will evaluate Alendronate Sodium Tablet for its safety in breastfeeding.
What is Alendronate Sodium Tablet used for?
Alendronate sodium tablets USP are a bisphosphonate indicated for: Treatment and prevention of osteoporosis in postmenopausal women (1.1, 1.2) Treatment to increase bone mass in men with osteoporosis (1.3) Treatment of glucocorticoid-induced osteoporosis (1.4) Treatment of Paget's disease of bone (1.5) Important limitations of use: The optimal duration of use has not been determined. The need for continued therapy should be re-evaluated on a periodic basis. (1.6) 1.1 Treatment of Osteoporosis in Postmenopausal Women Alendronate sodium tablets USP are indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women, alendronate sodium tablets USP increase bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures) [see Clinical Studies (14.1)]. 1.2 Prevention of Osteoporosis in Postmenopausal Women Alendronate sodium tablets USP are indicated for the prevention of postmenopausal osteoporosis [see Clinical Studies (14.2)]. 1.3 Treatment to Increase Bone Mass in Men With Osteoporosis Alendronate sodium tablets USP are indicated for treatment to increase bone mass in men with osteoporosis [see Clinical Studies (14.3)]. 1.4 Treatment of Glucocorticoid-Induced Osteoporosis Alendronate sodium tablets USP are indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density [see Clinical Studies (14.4)]. 1.5 Treatment of Paget's Disease of Bone Alendronate sodium tablets USP are indicated for the treatment of Paget’s disease of bone in men and women. Treatment is indicated in patients with Paget's disease of bone who have alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease [see Clinical Studies (14.5)]. 1.6 Important Limitations of Use The safety and effectiveness of alendronate sodium tablets USP for the treatment of osteoporosis are based on clinical data of four years duration. The optimal duration of use has not been determined. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis.
I am breastfeeding mother and I am using Alendronate Sodium Tablet. Can it have any bad effect on my kid? Shall I search for better alternative?
Alendronic acid is the one and only active ingredient present in Alendronate Sodium Tablet. Alendronic acid in itself is a low risk drug for lactation so it is easy to understand that Alendronate Sodium Tablet also comes in category of Low Risk item while breastfeeding. Below is the summary of Alendronic acid in breastfeeding.
Statement of Manufacturer/Labeler about breastfeeding usage
8.3 Nursing Mothers It is not known whether alendronate sodium is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when alendronate sodium is administered to nursing women.
Alendronate Sodium Tablet Breastfeeding Analsys
Alendronic acid while Breastfeeding Low Risk
CAS Number: 66376-36-1
It is composed by bisphosphonates. Most bisphosphonates are acidic compounds that achieve low plasma concentration. Both features make it unlikely excretion into the milk in clinically significant amount. Alendronate has shown very low plasma concentrations (<5 ng / ml). Intestinal absorption of bisphosphonates is very low even during fasting and is considered negligible in the presence of milk due to formation with the calcium of non absorbable compounds. A latest update no published data were found on excretion in the breast milk. Until more data about this drug regarding breastfeeding is available, safer known alternatives (e.g. pamidronate) should be of choice, especially in the neonatal period and in case of prematurity.
Alendronate Sodium Tablet Breastfeeding Analsys - 2
Alendronic acid while Breastfeeding
CAS Number: 66376-36-1
Limited evidence indicates that breastfeeding after cessation of long-term bisphosphonate treatment appears to have no adverse effects on the infant. Because no information is available on the use of alendronate during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. However, absorption of alendronate by a breastfed infant is unlikely. If the mother receives a bisphosphonate during pregnancy or nursing, some experts recommend monitoring the infant's serum calcium during the first 2 months postpartum.
I already used Alendronate Sodium Tablet and meanwhile I breastfed my baby should I be concerned?
During whole lactation period you shall first discuss with your doctor and then together you shall decide whether you shall take that drug or not however if you have already taken Alendronate Sodium Tablet then you shall inform your doctor, But you should not be worried too much as Alendronate Sodium Tablet comes in category of low risk drug.
I am nursing mother and my doctor has suggested me to use Alendronate Sodium Tablet, is it safe?
Though Alendronate Sodium Tablet dose not comes in category of safe drugs rather it comes in category of low risk but if your doctor is aware that you are breastfeeding your baby and has still recommended it then its advantages must be outweighing the risks.
If I am using Alendronate Sodium Tablet, will my baby need extra monitoring?
Who can I talk to if I have questions about usage of Alendronate Sodium Tablet in breastfeeding?
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week